Why Boehringer’s TL1A/IL23 bispecific bet could reshape IBD drug development
Find out why Boehringer is betting big on Simcere’s bispecific SIM0709 to challenge the IBD treatment ceiling.
Pharma & Biotech
Pharma & Biotech
Will TETRAPHARM’s TPC-026 unlock the chronic-care gap in metabolic disorders?
Can TPC-026 fill the gap after GLP-1s? Find out how TETRAPHARM’s novel compound could reshape long-term metabolic care.
Pharma & Biotech
What sets Hanmi’s GLP-1 strategy apart as efpeglenatide heads into Latin America
Hanmi taps Sanfer to launch GLP-1 drug efpeglenatide in Mexico. Find out what this deal reveals about Latin America’s obesity drug market strategy.
Pharma & Biotech
Is Skyhawk’s SKY-0515 the first disease-modifying breakthrough in Huntington’s disease?
Skyhawk’s SKY-0515 shows functional gains in Huntington’s disease. Find out how RNA modulation could alter the treatment landscape.
Pharma & Biotech
Tinlarebant moves closer to FDA review after Belite Bio finishes DRAGON II trial enrollment
Find out how Belite Bio’s DRAGON II milestone moves tinlarebant closer to FDA review as a potential first therapy for Stargardt disease.
Pharma & Biotech
Cognition Therapeutics advances regulatory strategy for zervimesine in an underserved neurodegenerative disease
Cognition Therapeutics aligns with FDA on zervimesine Phase 2b plans. Discover what this means for dementia with Lewy bodies drug development.
Pharma & Biotech
What Cloudbreak Pharma’s Phase 2 FDA meeting reveals about late-stage risk in ophthalmic drug development
Find out how Cloudbreak Pharma’s Phase 2 FDA meeting reshapes late-stage risk for CBT-004 and what it signals for ophthalmic drug development.
Pharma & Biotech
Imviva Biotech secures FDA orphan designation as CD7 CAR-T development faces execution challenges
FDA grants orphan drug designation to Imviva Biotech’s CTD402. Find out what this means for allogeneic CAR-T development in T-cell leukemia.
Pharma & Biotech
Can Genentech’s CT-388 challenge obesity drug giants with 22.5% weight loss and β-arrestin bias?
Genentech’s CT-388 hit 22.5% weight loss in Phase II. Find out what this means for obesity drugs, clinical durability, and market strategy in 2026.
Pharma & Biotech
Scancell’s late-stage push for iSCIB1+ reframes the risk calculus in advanced melanoma trials
FDA clears Scancell’s iSCIB1+ for Phase 3 testing in advanced melanoma. Discover what this means for immunotherapy risk, trial design, and competition.